K Alsaleh, H Al Zahwahry, A Bounedjar, M Oukkal, A Saadeddine, H Mahfouf, K Bouzid, A Bensalem, T Filali, H Abdel-Razeq, B Larbaoui, A Kandil, O Abulkhair, M Al Foheidi, M Ghosn, H Rasool, H Boussen, A Mezlini, A Haddaoui, J Ayari, M Al Ghamdi, H Errihani, N Abdel-Aziz, M Arafah, F Dabouz, M Bahadoor, S Kullab, J M Nabholtz
BACKGROUND: The most prevalent subtype of breast cancer (BC) is luminal hormonal-positive breast cancer. The neoadjuvant chemotherapy regimens have side effects, emphasizing the need to identify new startegies. OBJECTIVE: Analyze the complete pathologic response (pCR) rate and overall response in a low-risk hormone-positive subset of patients receiving neoadjuvant hormone treatment (NAHT) with or without Palbociclib (a CDK4/CDK6 inhibitor) to boost NAHT effectiveness...
January 21, 2023: Journal of Cancer Research and Clinical Oncology